Literature DB >> 10522726

Clinical and pathologic predictors of survival in patients with thymoma.

K B Wilkins1, E Sheikh, R Green, M Patel, S George, M Takano, M Diener-West, J Welsh, S Howard, F Askin, G B Bulkley.   

Abstract

OBJECTIVE: To evaluate the Johns Hopkins Hospital experience with 136 thymomas over the past 40 years. This number of patients allowed quantitative estimation of the independent influence of common clinicopathologic risk factors using multivariate analysis. SUMMARY BACKGROUND DATA: Thymomas vary widely in terms of recurrence and influence on overall survival. Several series have indicated the importance of initial tumor invasion, as well as the extent of surgical resection, as predictors of recurrence and survival after thymoma resection. However, findings have been equivocal when other predictors of prognosis were examined.
METHODS: The authors evaluated 136 patients seen at the Johns Hopkins Hospital between 1957 and 1997 with a pathologic diagnosis of thymoma. Demographic information, clinical staging data, surgical and adjuvant treatment details, and patient follow-up data were obtained from the patient record and from detailed patient or family interviews. Microscopic sections of all 136 patients were reviewed by two pathologists blinded to the clinical data. All data were analyzed by multivariate Cox regression analysis, which allowed the quantification of the independent predictive value of 12 putative clinicopathologic prognostic indicators.
RESULTS: Completeness of follow-up was 99%, 99%, and 98% of eligible patients at 5, 10, and 15 years, respectively. Forty percent of the patients had associated myasthenia gravis and 27% had a secondary primary malignancy. Overall patient survival rates were 71%, 56%, 44%, 38%, and 33% at 5, 10, 15, 20, and 25 years, respectively. Overall, the thymoma-related mortality rate was 14%; the nonthymoma-related mortality rate was 26%. Incomplete resection, preoperative absence of myasthenia gravis, and advanced Lattes/Bernatz pathologic class were found to be independent predictors of poorer overall survival.
CONCLUSIONS: These findings support a policy of aggressive, complete surgical resection of all thymomas when feasible. Thymoma behaves as a rather indolent tumor, with most deaths from causes unrelated to thymoma or its direct treatment. Clinicians should have an increased awareness of the possibility of second primary malignancies in patients with thymoma.

Entities:  

Mesh:

Year:  1999        PMID: 10522726      PMCID: PMC1420905          DOI: 10.1097/00000658-199910000-00012

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  34 in total

1.  Extended cervicomediastinal thymectomy in the integrated management of myasthenia gravis.

Authors:  G B Bulkley; K N Bass; G R Stephenson; M Diener-West; S George; P A Reilly; R R Baker; D B Drachman
Journal:  Ann Surg       Date:  1997-09       Impact factor: 12.969

2.  Thymic hyperplasia and neoplasia: a review of current concepts.

Authors:  G D Levine; J Rosai
Journal:  Hum Pathol       Date:  1978-09       Impact factor: 3.466

3.  Thymomas: clinicopathologic features, therapy, and prognosis.

Authors:  M A Batata; N Martini; A G Huvos; R I Aguilar; E J Beattie
Journal:  Cancer       Date:  1974-08       Impact factor: 6.860

4.  Cases of thymoma at the Massachusetts General Hospital.

Authors:  E W Wilkins; L H Edmunds; B Castleman
Journal:  J Thorac Cardiovasc Surg       Date:  1966-09       Impact factor: 5.209

5.  Thymoma: a clinical and pathological study of 65 cases.

Authors:  W R Salyer; J C Eggleston
Journal:  Cancer       Date:  1976-01       Impact factor: 6.860

6.  Recurrence of thymoma: clinicopathological features, therapy, and prognosis.

Authors:  Y Monden; K Nakahara; S Iioka; S Nanjo; K Ohno; Y Fujii; J Hashimoto; Y Kitagawa; A Masaoka; Y Kawashima
Journal:  Ann Thorac Surg       Date:  1985-02       Impact factor: 4.330

7.  Tumors of the thymus and thymic region: I. Clinicopathological studies on thymomas.

Authors:  N P Bergh; P Gatzinsky; S Larsson; P Lundin; B Ridell
Journal:  Ann Thorac Surg       Date:  1978-02       Impact factor: 4.330

8.  Results of surgical treatment for thymoma.

Authors:  F Shamji; F G Pearson; T R Todd; R J Ginsberg; R Ilves; J D Cooper
Journal:  J Thorac Cardiovasc Surg       Date:  1984-01       Impact factor: 5.209

9.  Follow-up study of thymomas with special reference to their clinical stages.

Authors:  A Masaoka; Y Monden; K Nakahara; T Tanioka
Journal:  Cancer       Date:  1981-12-01       Impact factor: 6.860

10.  Thymoma. A comparative study of clinical stages, histologic features, and survival in 200 cases.

Authors:  J M Verley; K H Hollmann
Journal:  Cancer       Date:  1985-03-01       Impact factor: 6.860

View more
  39 in total

Review 1.  [Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion].

Authors:  H-S Hofmann; K Wiebe
Journal:  Chirurg       Date:  2010-06       Impact factor: 0.955

2.  The contact length between the tumor contour and the lung on computed tomography is a risk factor for pleural recurrence after complete resection of thymoma.

Authors:  Taketo Kato; Shingo Iwano; Tetsuo Taniguchi; Koji Kawaguchi; Takayuki Fukui; Futoshi Ishiguro; Koichi Fukumoto; Shota Nakamura; Akihiro Hirakawa; Kohei Yokoi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-02-08

3.  Thymoma. Analysis of prognostic factors.

Authors:  M Sonobe; M Nakagawa; M Ichinose; N Ikegami; M Nagasawa; T Shindo
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-01

4.  Undifferentiated pleiomorphic sarcoma simultaneously occuring with thymoma.

Authors:  Christos Simoglou; Nikolaos Tsolakis
Journal:  J Thorac Dis       Date:  2014-09       Impact factor: 2.895

5.  Editorial on "Postoperative survival for patients with thymoma complicating myasthenia gravis-preliminary retrospective results of the ChART database".

Authors:  Alper Toker; Berker Ozkan
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

6.  Intra-Thoracic Chemo-Hyperthermia for pleural recurrence of thymomas.

Authors:  Jean-Michel Maury; Gabrielle Drevet; Francois Tronc; Nicolas Girard
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

7.  Editorial: pleural recurrence of thymoma-what is the value of intra-thoracic chemo-hyperthermia?

Authors:  Anja C Roden; Julian R Molina
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

Review 8.  Pediatric thymomas: report of two cases and comprehensive review of the literature.

Authors:  Annabelle L Fonseca; Doruk E Ozgediz; Emily R Christison-Lagay; Frank C Detterbeck; Michael G Caty
Journal:  Pediatr Surg Int       Date:  2013-12-10       Impact factor: 1.827

9.  Thymic neoplasm: a rare disease with a complex clinical presentation.

Authors:  Omar M Rashid; Anthony D Cassano; Kazuaki Takabe
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

10.  Triad of thymoma, myasthenia gravis and pure red cell aplasia combined with Sjögren's syndrome.

Authors:  Koichi Fujiu; Ryuzo Kanno; Yutaka Shio; Jyun Ohsugi; Yoshihiro Nozawa; Mitsukazu Gotoh
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2004-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.